What happened to CureVac stock since its IPO?
Since its IPO in mid-August, CureVac N.V. (NASDAQ: CVAC) is taking investors on a wild ride. CVAC stock exploded out of the gate, topping $85 intra-day. Yet the market is unkind to investors since then.
Will CureVac be worth $100 more in 200 days?
Some of the BIG pharmaceuticals plan to rework their vaccines to target Omicron in 100 days, if CureVac could have its second gen even in 200 days, that would be awesome and would put them back over $100 where they belong. we are expecting a raise to 150#$%$ once the final results will be released positive of course .
Is CVAC stock a buy at $85?
CVAC stock exploded out of the gate, topping $85 intra-day. Yet the market is unkind to investors since then. Investor interest is waning. Founded in 2000, the biomedical research company is developing a new class of drugs.
Can CureVac boost antibody levels?
Curevac ceo Haas said we are working with full speed now!!! When AstraZeneca, Novavax, Johnson & Johnson and Curevac were given as boosters, they increased antibody levels for either initial vaccine. i wonder when people notice that the mra companies not only research on covid vaccines.
See more
How effective is CureVac?
What is the difference between Pfizer and CureVac?
London (CNN Business) Shares in CureVac plummeted on Thursday after the German biotech company said that interim trial results showed its experimental Covid-19 vaccine was only 47% effective in preventing symptomatic disease.
The biotech's COVID-19 vaccine candidate no longer appears to be viable
It's delivered in lipid or fat particles as those two vaccines are. But both Moderna and Pfizer modified the mRNA, while the CureVac vaccines uses unmodified mRNA.
What happened
George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.
So what
Shares of German biotech CureVac ( NASDAQ:CVAC) are down by a hefty 49.9% as of 9:47 a.m. EDT Thursday morning. The biotech's shares are getting walloped today in response to disappointing late-stage trial results for its COVID-19 vaccine candidate known as CVnCoV.
Now what
CureVac blamed the vaccine's poor efficacy -- compared to other mRNA vaccines already on the market -- on the large number of COVID-19 variants currently in circulation. The first round of mRNA vaccines were trialed before most of these variants became widespread.
What age group is CureVac?
Can CureVac stock bounce back soon? Wall Street was expecting a lot from this vaccine from a revenue generation standpoint, to put it mildly.
What is the clinical program of CV8102?
What does this mean for CureVac N.V.? Although CureVac's vaccine candidate demonstrated an efficacy of 53% among participants in the age group of 18 to 60 (77% against moderate and severe disease), the numbers still fall short of the current vaccines that are in place.
When did CureVac announce its clinical data?
Its clinical programs are CV8102, which it is evaluating in Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which it is investigating in Phase 1 clinical trial for potential vaccination against rabies.
Is CureVac repurposed?
On June 30, CureVac (NASDAQ: CVAC) announced final late-stage clinical data for its mRNA coronavirus vaccine candidate CVnCoV. Nobody was more disappointed than the German government, which had invested more than 300 million euros into the vaccine candidate's research and development efforts.
Vaccine Data Readout To Move CureVac Stock
German bio tech firm CureVac could allow its network of manufacturing partners to be repurposed to make vaccines developed by other companies should its own experimental shot fail, its chief executive told Reuters on Thursday. The German company saw billions of euros wiped from its market value on Thursday after its COVID-19 vaccine proved only 47% effective in an initial trial read-out, denting investor confidence in its ability to take on rival shots. "At the moment we are of course fully committed to obtain authorisation, the data will show," CureVac CEO Franz-Werner Haas told Reuters TV, referring to a final read-out that is still pending.
Cash on Hand
Even though the firm has no vaccine on the market, countries are lining up pre-orders. For example, the European Union is set to order 225 million Covid-19 vaccine doses from CureVac. The EU Commission President said, “Each round of talks that we conclude with the pharmaceutical industry brings us closer to beating this virus.
Opportunity
The nearly 13.3 million shares sold at $14 – $16 at the IPO adds around $200 million in cash. The over-allotment of ~2 million shares adds another $30 million. The cash balance is an important data point for biotech investors.
Price Target
The Covid-19 vaccine company list is getting longer with each passing quarter. Moderna is the best known among the players. Plus, it raised billions in the last year and has the support of the National Institutes of Health (NIH). So, investors need to weigh CureVac’s overall portfolio of drugs in development.